CN1228703A - 用于治疗由自由基引发的疾病的螯合剂及其金属螯合物 - Google Patents

用于治疗由自由基引发的疾病的螯合剂及其金属螯合物 Download PDF

Info

Publication number
CN1228703A
CN1228703A CN97197438A CN97197438A CN1228703A CN 1228703 A CN1228703 A CN 1228703A CN 97197438 A CN97197438 A CN 97197438A CN 97197438 A CN97197438 A CN 97197438A CN 1228703 A CN1228703 A CN 1228703A
Authority
CN
China
Prior art keywords
group
chelate
purposes
formula
metallo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN97197438A
Other languages
English (en)
Chinese (zh)
Inventor
J·O·G·卡尔松
P·于恩格
R·托沃特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed Imaging AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging AS filed Critical Nycomed Imaging AS
Publication of CN1228703A publication Critical patent/CN1228703A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Semiconductor Lasers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Manufacture And Refinement Of Metals (AREA)
CN97197438A 1996-06-24 1997-06-24 用于治疗由自由基引发的疾病的螯合剂及其金属螯合物 Pending CN1228703A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613182.6A GB9613182D0 (en) 1996-06-24 1996-06-24 Method
GB9613182.6 1996-06-24

Publications (1)

Publication Number Publication Date
CN1228703A true CN1228703A (zh) 1999-09-15

Family

ID=10795775

Family Applications (2)

Application Number Title Priority Date Filing Date
CN97197438A Pending CN1228703A (zh) 1996-06-24 1997-06-24 用于治疗由自由基引发的疾病的螯合剂及其金属螯合物
CN97197429A Pending CN1228694A (zh) 1996-06-24 1997-06-24 使用锰化合物降低抗肿瘤药物心脏毒性的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN97197429A Pending CN1228694A (zh) 1996-06-24 1997-06-24 使用锰化合物降低抗肿瘤药物心脏毒性的方法

Country Status (14)

Country Link
US (2) US6258828B1 (enExample)
EP (2) EP0910360B1 (enExample)
JP (2) JP4359651B2 (enExample)
CN (2) CN1228703A (enExample)
AT (2) ATE228361T1 (enExample)
AU (2) AU720621B2 (enExample)
BR (1) BR9709942A (enExample)
CA (2) CA2259150A1 (enExample)
DE (2) DE69717447T2 (enExample)
GB (1) GB9613182D0 (enExample)
IL (1) IL127733A0 (enExample)
NO (2) NO985917L (enExample)
NZ (2) NZ333357A (enExample)
WO (2) WO1997049390A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481295A (zh) * 2009-07-06 2012-05-30 普莱制药公司 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001527072A (ja) 1997-12-23 2001-12-25 ニユコメド・イメージング・アクシエセルカペト 一酸化窒素を放出するキレート化剤およびその治療上の使用
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
KR101353140B1 (ko) 1999-10-01 2014-01-20 디엠아이 바이오사이언시스, 인크 금속 결합 화합물 및 그의 용도
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2823977B1 (fr) * 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
ES2388064T3 (es) 2004-04-22 2012-10-08 Celator Pharmaceuticals, Inc. Formulaciones liposomales de agentes de antraciclina y análogos de citidina
CA2880727C (en) 2005-08-31 2019-05-07 Neil P. Desai Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
WO2009078794A1 (en) * 2007-12-14 2009-06-25 Pledpharma Ab Compounds for use in the treatment of cancer
ES2792062T3 (es) 2011-05-09 2020-11-06 Mayo Found Medical Education & Res Tratamientos contra el cáncer
CA2862736C (en) 2012-01-05 2020-09-08 Pledpharma Ab Mixed metal complexes and methods
ES2899643T3 (es) 2012-10-01 2022-03-14 Mayo Found Medical Education & Res Tratamientos para el cáncer
MX376321B (es) 2012-11-02 2025-03-07 Egetis Therapeutics Ab Usos para el tratamiento de cancer.
AU2015274408A1 (en) 2014-06-13 2017-01-12 Mayo Foundation For Medical Education And Research Treating lymphomas
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
WO2017165439A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP3506950A1 (en) 2016-09-01 2019-07-10 Mayo Foundation for Medical Education and Research Methods and compositions for targeting t-cell cancers
CA3035378A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Carrier-pd-l1 binding agent compositions for treating cancers
EP3509643A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
AU2017324335A1 (en) 2016-09-06 2019-03-28 Mayo Foundation For Medical Education And Research Methods of treating PD-L1 expressing cancer
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444380A1 (es) * 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US5223243A (en) * 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481295A (zh) * 2009-07-06 2012-05-30 普莱制药公司 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法

Also Published As

Publication number Publication date
IL127733A0 (en) 1999-10-28
JP4359651B2 (ja) 2009-11-04
NO985917D0 (no) 1998-12-17
WO1997049409A1 (en) 1997-12-31
AU3268997A (en) 1998-01-14
EP0910360B1 (en) 2002-11-27
ATE225178T1 (de) 2002-10-15
GB9613182D0 (en) 1996-08-28
CA2259150A1 (en) 1997-12-31
CA2258299A1 (en) 1997-12-31
NZ333315A (en) 2000-07-28
EP0936915B1 (en) 2002-10-02
DE69716104T2 (de) 2003-05-28
NO985916D0 (no) 1998-12-17
CN1228694A (zh) 1999-09-15
AU720621B2 (en) 2000-06-08
EP0910360A1 (en) 1999-04-28
DE69716104D1 (de) 2002-11-07
EP0936915A1 (en) 1999-08-25
NZ333357A (en) 2000-08-25
JP2000514044A (ja) 2000-10-24
JP2000513351A (ja) 2000-10-10
DE69717447T2 (de) 2003-09-11
US6147094A (en) 2000-11-14
WO1997049390A1 (en) 1997-12-31
DE69717447D1 (de) 2003-01-09
BR9709942A (pt) 1999-08-10
NO985917L (no) 1999-01-25
AU3268897A (en) 1998-01-14
US6258828B1 (en) 2001-07-10
JP4162263B2 (ja) 2008-10-08
AU720570B2 (en) 2000-06-08
NO985916L (no) 1999-01-25
ATE228361T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
CN1228703A (zh) 用于治疗由自由基引发的疾病的螯合剂及其金属螯合物
TW386877B (en) Antitumour compositions containing taxane derivatives
JP2001247459A (ja) 癌の組み合わせ療法
JP5563452B2 (ja) 一酸化炭素による胃潰瘍の予防
CN105012272B (zh) 一种可用于治疗骨转移癌的氧化还原敏感骨靶向胶束
KR20010108229A (ko) 아스코르브산 및 리포산의 조합물을 암치료에 사용하는 용도
JP2007529528A5 (enExample)
JP2021521209A (ja) 鉄過剰症の治療のための組成物及び方法
JP2015057409A (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
Qian et al. Evaluation of cisplatin-hydrogel for improving localized antitumor efficacy in gastric cancer
US8076371B2 (en) Gallium compositions for the treatment of liver cancer and methods of use
CN111072679A (zh) 一种非周边季铵基修饰锌酞菁及其制备方法和应用
CN101917993A (zh) 用于治疗癌症的化合物
EP3888649B1 (en) Cannflavin a for use in promoting wound healing and treating or preventing diabetic feet
JP4395368B2 (ja) 細胞殺傷活性を有するカルシウム塩
CA3079031C (en) Formulation containing a-decarbonized-5-alpha androstane compound for increasing white blood cell and use thereof
Graham The toxicity of sterile filtrate from parodontal pockets
CN110327394A (zh) 黄皮果或其果皮中降血糖成分的提取方法
JP2002145789A (ja) 過酸化脂質抑制剤
US20150099718A1 (en) Heparin-based compositions and methods for the inhibition of metastasis
CN104974187A (zh) 菲罗啉类衍生物及其制备方法和应用
JP2015520121A (ja) ベンゼンポリカルボン酸化合物及びその薬剤としての使用
CA2482687A1 (en) Treatment of mesothelioma
KR102035481B1 (ko) 점토광물 복합체를 포함하는 염증성 대장염의 예방, 개선 및 치료용 조성물
RU2375066C2 (ru) Способ профилактики ранних послеоперационных тромбоэмболических осложнений

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication